Eugit Therapeutics - About the company
Eugit Therapeutics is a seed company based in Cambridge (United States), founded in 2022 by Nizar Batada and Yoshinori Fukazawa. It operates as a Developer of T-cell-based cancer therapeutics. Eugit Therapeutics has raised $500K in funding from Y Combinator. The company has 3237 active competitors, including 1114 funded and 782 that have exited. Its top competitors include companies like Jazz Pharmaceuticals, Kite Pharma and Advanced Accelerator Applications.
Company Details
Developer of T-cell-based cancer therapeutics. The T-cells are for the cancers that respond poorly to existing alpha-beta T cell-based immunotherapies, like breast, ovarian, and prostate cancers.
Key Metrics
Founded Year
2022
Location
Cambridge, United States
Stage
Seed
Total Funding
$500K in 2 rounds
Latest Funding Round
Investors
Ranked
1877th among 3237 active competitors
Employee Count
2 as on Mar 31, 2026
Similar Companies
Sign up to download Eugit Therapeutics' company profile
Eugit Therapeutics's funding and investors
Eugit Therapeutics has raised a total funding of $500K over 2 rounds. Its first funding round was on 2022. Its latest funding round was a Grant (prize money) round on Aug 15, 2024 for $*****. 1 investor participated in its latest round. Eugit Therapeutics has 2 institutional investors.
Here is the list of recent funding rounds of Eugit Therapeutics:
Date of Funding | Funding Amount | Round Name | Post-Money Valuation | Revenue Multiple | Lead Investors | Other Investors |
|---|---|---|---|---|---|---|
Aug 15, 2024 | 9571981 | Grant (prize money) | 6454372 | 7898888 | 9607248 | 4534915 |
2022 | 6134 | Seed | 9542 | 5480 | 3576 |
Access funding benchmarks and valuations. Sign up today!View details of Eugit Therapeutics's funding rounds and investors
Eugit Therapeutics' founders and board of directors
Founder? Claim ProfileThe founders of Eugit Therapeutics are Nizar Batada and Yoshinori Fukazawa. Nizar Batada is the CEO of Eugit Therapeutics.
Here are the details of Eugit Therapeutics' key team members:
- Nizar Batada: Founder & CEO of Eugit Therapeutics and founder of 1 other company.
- Yoshinori Fukazawa: Co-Founder, VP of Research of Eugit Therapeutics.
View details of Eugit Therapeutics's Founder profiles and Board Members
Eugit Therapeutics' employee count trend
Eugit Therapeutics has 2 employees as of Mar 26. Here is Eugit Therapeutics's employee count trend over the years:
Uncover Eugit Therapeutics' growth story! Sign up today!
Access Tracxn on any website
Install Tracxn ExtensionOur Google Chrome extension lets you view company details while browsing their websites
Eugit Therapeutics's Competitors and alternates
Top competitors of Eugit Therapeutics include Jazz Pharmaceuticals, Kite Pharma and Advanced Accelerator Applications. Here is the list of Top 10 competitors of Eugit Therapeutics, ranked by Tracxn score:
Get insights and benchmarks for competitors of 2M+ companies! Sign up today!
Rank | Company Details | Short Description | Total Funding | Investors | Tracxn Score |
|---|---|---|---|---|---|
1st |  Jazz Pharmaceuticals 2003, Dublin (Ireland), Public | Developer of novel biopharmaceutical medicines for unmet medical needs | $265M | 82/100 | |
2nd | Kite Pharma 2009, Los Angeles (United States), Acquired | Developer of cancer immunotherapy products using genetic engineering | $97.7M | 79/100 | |
3rd |  Advanced Accelerator Applications 2002, Saint Genis Pouilly (France), Acquired | Novartis company, developing molecular nuclear medicine theranostics | $56.1M | 78/100 | |
4th |  Sana Biotechnology 2018, Seattle (United States), Public | Developer of genetically engineered cell therapies for multiple disorders | $821M | 75/100 | |
5th | Juno Therapeutics 2013, Seattle (United States), Acquired | Global biopharmaceutical company discovering, developing, and delivering innovative medicines | $317M | 74/100 | |
6th | C4 Therapeutics 2016, Cambridge (United States), Public | Developer of small molecule drugs for treating cancer | $223M | 74/100 | |
7th | Immunocore 2008, Abingdon (United Kingdom), Public | Developer of drugs based on T-Cell receptor technology for the treatment of cancer | $601M | 74/100 | |
8th | FibroGen 1993, San Francisco (United States), Public | Treatments for anemia and fibrosis by exploiting connective tissue growth factor (CTGF) and hypoxia-inducible factor (HIF) biology. | $215M | 72/100 | |
9th | Blueprint Medicines 2008, Cambridge (United States), Acquired | Developer of selective kinase inhibitors for patients with genomically defined cancers | $115M | 72/100 | |
10th |  BeiGene 2010, Cambridge (United States), Public | Developer of targeted and immune-oncology drugs against cancer | $172M | 72/100 | |
1877th | Eugit Therapeutics 2022, Cambridge (United States), Seed | Developer of T-cell-based cancer therapeutics | $500K | 30/100 |
Get insights and benchmarks for competitors of 2M+ companies! Sign up today!Looking for more details on Eugit Therapeutics's competitors? Click here to see the top ones
Eugit Therapeutics's Investments and acquisitions
Eugit Therapeutics has made no investments or acquisitions yet.
Reports related to Eugit Therapeutics
Here is the latest report on Eugit Therapeutics's sector:
Are you a Founder ?
FAQs about Eugit Therapeutics
Explore our recently published companies
- Qubotics - Bengaluru based, 2020 founded, Unfunded company
- LRN - New York City based, 1994 founded, Late Stage company
- Integrate - Seattle based, 2022 founded, Series A company
- Sanitech Engineers - Mumbai based, 1994 founded, Unfunded company
- DUSQ - San Francisco based, 2024 founded, Seed company
- MyManah - Bengaluru based, 2025 founded, Unfunded company
